Amicus Therapeutics (FOLD)
NASDAQ:FOLD
Top Page
Amicus
(NASDAQ:FOLD)
Select Model
Select Model
Rating:59Neutral
Price Target:
$15.00
▲(3.66% Upside)
Action:ReiteratedDate:03/22/26
The score is driven primarily by improving operating fundamentals and cash-flow inflection, but capped by balance-sheet leverage and lack of consistent profitability (negative P/E). Technicals are supportive yet overbought, while the BioMarin acquisition approval adds a meaningful positive catalyst tempered by remaining regulatory-close risk.
Positive Factors
High gross margins with scalable revenue
Sustained revenue scaling combined with very high gross margins (~88–91%) gives durable operating leverage: product revenue growth should convert efficiently to gross profit, supporting long-term margin sustainability and reinvestment capacity even as operating expenses fluctuate.
Negative Factors
Meaningful leverage for earnings profile
Debt materially exceeds equity for the current earnings base, creating interest and refinancing pressure. If profitability or cash flow weakens, leverage limits strategic optionality and heightens solvency risk over the next several quarters absent continued cash generation or deleveraging actions.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins with scalable revenue
Sustained revenue scaling combined with very high gross margins (~88–91%) gives durable operating leverage: product revenue growth should convert efficiently to gross profit, supporting long-term margin sustainability and reinvestment capacity even as operating expenses fluctuate.
Read all positive factors
Amicus (FOLD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.54B
Dividend YieldN/A
Average Volume (3M)3.69M
Price to Earnings (P/E)―
Beta (1Y)0.45
Revenue Growth21.28%
EPS Growth87.30%
CountryUS
Employees499
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.01
Shares Outstanding314,000,700
10 Day Avg. Volume3,418,034
30 Day Avg. Volume3,687,117
Financial Highlights & Ratios
PEG Ratio3.17
Price to Book (P/B)16.01
Price to Sales (P/S)6.92
P/FCF Ratio147.11
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue7.58
Enterprise Value/Gross Profit8.63
Enterprise Value/Ebitda89.38
Forecast
1Y Price Target
$14.50Price Target Upside0.21% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)0.32
Revenue Forecast (FY)$750.73M
Amicus Business Overview & Revenue Model
Company Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adu...
How the Company Makes Money
null...
Amicus Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down total company revenue across regions so you can see which markets drive growth, identify concentration risk, and spot exposure to currency swings, payer pressure, or local regulatory issues that could impact future results.
Breaks down total company revenue across regions so you can see which markets drive growth, identify concentration risk, and spot exposure to currency swings, payer pressure, or local regulatory issues that could impact future results.
Data provided by:
The Fly
The FlyAmicus Earnings Call Summary
Earnings Call Date:Nov 04, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The earnings call for Amicus Therapeutics highlights strong financial performance with notable revenue growth and GAAP profitability, driven by their flagship products and global market expansion. Despite some increase in costs and early-stage profitability, the company's strategic focus on expanding their product pipeline and market presence suggests a positive outlook.Positive Updates
Strong Revenue Growth and GAAP Profitability
Amicus Therapeutics reported a 19% increase in total revenue over the same period in 2024, marking the first quarter of 2025 with positive GAAP net income of $17.3 million.
Negative Updates
Cost of Goods Sold Increase
Cost of goods sold as a percentage of net sales increased to 12% for Q3 compared to 9% in the same period last year.
Read all updates
Q3-2025 Updates
Positive
Negative
Strong Revenue Growth and GAAP Profitability
Amicus Therapeutics reported a 19% increase in total revenue over the same period in 2024, marking the first quarter of 2025 with positive GAAP net income of $17.3 million.
Read all positive updates
Company Guidance
During the Amicus Therapeutics Third Quarter 2025 Financial Results Conference Call, the company provided robust guidance across several metrics. They reported a 19% increase in total quarterly revenue, reaching $169.1 million, with Galafold revenue growing by 15% and Pombiliti and Opfolda by 42% at constant exchange rates. The company reaffirmed its full-year 2025 revenue growth guidance of 15% to 22% and projected total sales of $1 billion by 2028 for its two commercial products. Additionally, Amicus highlighted the successful enrollment of over 90% in the ACTION3 trial for DMX-200, targeting FSGS, and reiterated its confidence in achieving GAAP net income for the second half of the year. The company emphasized its strategic focus on continued revenue growth, market expansion, and new patient starts, particularly citing a 13% year-over-year increase in Galafold patient growth and a 45% revenue increase for Pombiliti and Opfolda.Amicus Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
44
Neutral
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 634.21M | 528.29M | 399.36M | 329.23M | 305.51M |
| Gross Profit | 553.82M | 475.35M | 362.03M | 290.63M | 271.05M |
| EBITDA | 53.81M | 29.39M | -92.08M | -199.58M | -202.87M |
| Net Income | -27.11M | -56.11M | -151.58M | -236.57M | -250.46M |
Balance Sheet | |||||
| Total Assets | 949.87M | 785.03M | 777.88M | 724.17M | 905.14M |
| Cash, Cash Equivalents and Short-Term Investments | 293.54M | 249.95M | 286.20M | 293.60M | 482.50M |
| Total Debt | 483.32M | 443.64M | 445.06M | 452.12M | 440.13M |
| Total Liabilities | 675.63M | 590.99M | 617.71M | 601.12M | 597.77M |
| Stockholders Equity | 274.24M | 194.04M | 160.17M | 123.05M | 307.37M |
Cash Flow | |||||
| Free Cash Flow | 29.85M | -37.44M | -76.53M | -170.34M | -206.38M |
| Operating Cash Flow | 33.15M | -33.89M | -69.09M | -166.57M | -202.49M |
| Investing Cash Flow | -46.43M | -560.00K | 98.06M | 92.32M | 78.76M |
| Financing Cash Flow | 610.00K | 5.12M | 61.68M | -7.46M | 212.07M |
Amicus Technical Analysis
Positive
14.47
Price Trends
14.35
Positive
13.14
Positive
10.28
Positive
Market Momentum
0.05
Positive
71.57
Negative
84.92
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FOLD, the sentiment is Positive. The current price of 14.47 is above the 20-day moving average (MA) of 14.41, above the 50-day MA of 14.35, and above the 200-day MA of 10.28, indicating a bullish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 71.57 is Negative, neither overbought nor oversold. The STOCH value of 84.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FOLD.
Amicus Risk Analysis
Amicus disclosed 71 risk factors in its most recent earnings report. Amicus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amicus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | $3.05B | 13.32 | 24.32% | ― | 25.56% | 44.42% | |
62 Neutral | $5.01B | -10.43 | -65.80% | ― | ― | -27.70% | |
59 Neutral | $4.54B | -161.97 | -12.02% | ― | 21.28% | 87.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.82B | -8.55 | -71.66% | ― | -9.21% | -8.84% | |
47 Neutral | $2.92B | ― | -79.16% | ― | 114.22% | 77.02% | |
43 Neutral | $2.55B | -13.21 | -32.80% | ― | ― | -34.96% |
* Healthcare Sector Average
FOLD
Amicus
14.47
7.58
110.01%
CPRX
Catalyst Pharma
24.99
2.25
9.89%
TVTX
Travere Therapeutics
31.67
17.32
120.70%
OCUL
Ocular Therapeutix
8.34
1.50
21.93%
IMVT
Immunovant
24.61
9.71
65.17%
IRON
Disc Medicine
66.85
28.15
72.74%
Amicus Corporate Events
M&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
Amicus Stockholders Approve BioMarin Acquisition at Special Meeting
Positive
Mar 3, 2026
On March 3, 2026, stockholders of Amicus Therapeutics approved the company’s acquisition by BioMarin Pharmaceutical, with approximately 74.79% of eligible shares represented at a special virtual meeting and an overwhelming majority voting in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.